title: [Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes].
abstract: OBJECTIVE
  The progressive accumulation of iron in the organism contribute to one of the most important problems of morbidity and mortality in patients with myelodysplastic syndrome (MDS). We present an observational protocol, multicentre, open and non-aleatheorised, in patients diagnosed with MDS on transfusional regime with iron overload. The study was meant to prove the effectiveness of the parenteral treatment with desferrioxamine using continuous devices of subcutaneous profusion and evaluate the evolution of iron overload as well as transfusional requirements.
  
  
  METHODS
  There were 28 patients (12 men and 16 women), 12 AR, 15 AS and 1 unknown. Average monitoring lasted 13.5 months and there was a gradual loss of patients. 11 of them had gone during the first year.
  
  
  RESULTS
  After 12 months the average of ferritin decreased by 258.51 ng/dl (DE 1208.04; p = 9.4) and after 24 months, it decreased by 979.6 ng/dl (DE 810.31; p = 0.1). After 12 months the average of requirements increased by 60.57 gHb/month (DE 183.7; p = 0.029) and after 24 months, it increased by 167.3 g/Hb/month (DE 406.5; p = 0.36).
  
  
  CONCLUSIONS
  Desferroxiamine treatment is effective at least to prevent an iron overload in these patients, and therefore should be incorporated in the clinical practice.
authors.affiliation: Servicio de Hematología y Hemoterapia, Hospital Clínico San Carlos, Madrid, España. fgonzalezf@aehh.org
authors.forename: Fernando Ataúlfo
authors.initials: FA
authors.lastname: González
authors.forename: Beatriz
authors.initials: B
authors.lastname: Arrizabalaga
authors.forename: Ana
authors.initials: A
authors.lastname: Villegas
authors.forename: Dora
authors.initials: D
authors.lastname: Alonso
authors.forename: Mercedes
authors.initials: M
authors.lastname: Castro
authors.forename: Angel
authors.initials: A
authors.lastname: Remacha
authors.forename: Aurora
authors.initials: A
authors.lastname: del Arco
authors.forename: Guillermo
authors.initials: G
authors.lastname: Martín Núñez
mesh_terms: D000368:Aged; D000753:Anemia, Refractory / Q000150:complications; D000756:Anemia, Sideroblastic / Q000150:complications; D001803:Blood Transfusion; D003676:Deferoxamine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D007502:Iron Chelating Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D019190:Iron Overload / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy*
chemical_list: D007502:Iron Chelating Agents; D005293:Ferritins; D003676:Deferoxamine